{"title":"Aurevoir à une personne remarquable du JOGC, Dr Tulandi","authors":"Diane Francoeur MD, FRCSC, MHCM, ICD.D, Lynn Murphy-Kaulbeck MD, MMgmt, MSC, FRCSC","doi":"10.1016/j.jogc.2024.102596","DOIUrl":"https://doi.org/10.1016/j.jogc.2024.102596","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141606214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.jogc.2024.102593
Paul J. Yong MD, PhD
{"title":"Extraits de la littérature médicale mondiale : gynécologie","authors":"Paul J. Yong MD, PhD","doi":"10.1016/j.jogc.2024.102593","DOIUrl":"https://doi.org/10.1016/j.jogc.2024.102593","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141606216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1016/j.jogc.2024.102591
Wendy Wolfman MD, Olga Bougie MD, Innie Chen MD, Yale Tang MD, Susan Goldstein MD, Jeanne Bouteaud MD
Objective
To formulate strategies for clinical assessments for endometrial thickening on ultrasound in a postmenopausal woman without bleeding.
Target population
Postmenopausal women of any age.
Outcomes
To reduce unnecessary invasive interventions and investigations in women with asymptomatic endometrial thickening while selectively investigating women at risk for endometrial cancer.
Benefits, harms, and costs
It is anticipated that the adoption of these recommendations would save postmenopausal women unnecessary anxiety, pain, and risk of procedural complications. It is also expected to decrease the cost to the health care system by eliminating unnecessary interventions.
Evidence
English language articles from Medline, Cochrane, and PubMed databases for relevant peer-reviewed articles dating from 1995 to 2022 (e.g., asymptomatic endometrial thickness, endometrial cancer, postmenopausal bleeding, transvaginal ultrasound, endometrial biopsy, cervical stenosis, hormone therapies and the endometrium, tamoxifen, tibolone, aromatase inhibitors). Results were restricted to systematic reviews and meta-analyses, randomized controlled trials/controlled clinical trials, and observational studies.
Validation Methods
The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See Appendix A (Tables A1 for definitions and A2 for interpretations of strong and conditional [weak] recommendations).
Intended Audience
Physicians, including gynaecologists, obstetricians, family physicians, radiologists, pathologists, and internists; nurse practitioners and nurses; medical trainees, including medical students, residents, and fellows; and other providers of health care of the postmenopausal population.
Social Media Abstract
Postmenopausal women often have a thickening of the lining of the uterus found during ultrasound. Without bleeding, an endometrium <11 mm is rarely a serious problem but should be evaluated by a health care provider.
SUMMARY STATEMENTS
1.
Asymptomatic endometrial thickening >5 mm is found in 3%–15% of postmenopausal women depending on the population studied (moderate).
2.
Ninety percent of postmenopausal women with endometrial cancer present with bleeding (high).
3.
In postmenopausal women without bleeding and an endometrium <11 mm, the incidence of endometrial cancer is approximately 1% (high).
4.
Endometrial biopsy is an accurate procedure if an adequate tissue sample is obtained in a patient with global
{"title":"Guideline No. 451: Asymptomatic Endometrial Thickening in Postmenopausal Women","authors":"Wendy Wolfman MD, Olga Bougie MD, Innie Chen MD, Yale Tang MD, Susan Goldstein MD, Jeanne Bouteaud MD","doi":"10.1016/j.jogc.2024.102591","DOIUrl":"10.1016/j.jogc.2024.102591","url":null,"abstract":"<div><h3>Objective</h3><p>To formulate strategies for clinical assessments for endometrial thickening on ultrasound in a postmenopausal woman without bleeding.</p></div><div><h3>Target population</h3><p>Postmenopausal women of any age.</p></div><div><h3>Outcomes</h3><p>To reduce unnecessary invasive interventions and investigations in women with asymptomatic endometrial thickening while selectively investigating women at risk for endometrial cancer.</p></div><div><h3>Benefits, harms, and costs</h3><p>It is anticipated that the adoption of these recommendations would save postmenopausal women unnecessary anxiety, pain, and risk of procedural complications. It is also expected to decrease the cost to the health care system by eliminating unnecessary interventions.</p></div><div><h3>Evidence</h3><p>English language articles from Medline, Cochrane, and PubMed databases for relevant peer-reviewed articles dating from 1995 to 2022 (e.g., asymptomatic endometrial thickness, endometrial cancer, postmenopausal bleeding, transvaginal ultrasound, endometrial biopsy, cervical stenosis, hormone therapies and the endometrium, tamoxifen, tibolone, aromatase inhibitors). Results were restricted to systematic reviews and meta-analyses, randomized controlled trials/controlled clinical trials, and observational studies.</p></div><div><h3>Validation Methods</h3><p>The authors rated the quality of evidence and strength of recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. See <span>Appendix A</span> (<span>Tables A1</span> for definitions and <span>A2</span> for interpretations of strong and conditional [weak] recommendations).</p></div><div><h3>Intended Audience</h3><p>Physicians, including gynaecologists, obstetricians, family physicians, radiologists, pathologists, and internists; nurse practitioners and nurses; medical trainees, including medical students, residents, and fellows; and other providers of health care of the postmenopausal population.</p></div><div><h3>Social Media Abstract</h3><p>Postmenopausal women often have a thickening of the lining of the uterus found during ultrasound. Without bleeding, an endometrium <11 mm is rarely a serious problem but should be evaluated by a health care provider.</p></div><div><h3>SUMMARY STATEMENTS</h3><p></p><ul><li><span>1.</span><span><p>Asymptomatic endometrial thickening >5 mm is found in 3%–15% of postmenopausal women depending on the population studied (<em>moderate</em>).</p></span></li><li><span>2.</span><span><p>Ninety percent of postmenopausal women with endometrial cancer present with bleeding (<em>high</em>).</p></span></li><li><span>3.</span><span><p>In postmenopausal women without bleeding and an endometrium <11 mm, the incidence of endometrial cancer is approximately 1% (<em>high</em>).</p></span></li><li><span>4.</span><span><p>Endometrial biopsy is an accurate procedure if an adequate tissue sample is obtained in a patient with global","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141432166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"What Is the Future of Radical Hysterectomy? Commentary on the Indication for Minimally Invasive Surgery for Cervical Cancer ≤2 cm","authors":"Kenro Chikazawa MD, PhD , Ken Imai MD , Tomoyuki Kuwata MD, PhD , Ryo Konno MD, PhD","doi":"10.1016/j.jogc.2023.102242","DOIUrl":"https://doi.org/10.1016/j.jogc.2023.102242","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141606335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-29DOI: 10.1016/j.jogc.2024.102604
Objectives
This prospective single-arm study was conducted to understand the expulsion rate of the gestational sac in the management of early pregnancy loss (EPL).
Methods
We recruited 441 participants; 188 met the eligibility criteria. Participants were 18 years of age and older who experienced a confirmed EPL (<12 weeks gestational age) defined by an intrauterine pregnancy with a non-viable embryonic or anembryonic gestational sac with no fetal heart activity. Participants were given 200 mg of mifepristone pre-treatment orally followed by 2 doses of misoprostol 800 μg vaginally after 24 and 48 hours. Participants were seen in follow-up on day 14 to confirm the absence of a gestational sac, classified as treatment success. For failed treatment (defined by retained gestational sac), we offered expectant management or a third dose of misoprostol and/or dilatation and curettage. We followed all participants for 30 days. We collected data on overtreatment for retained products of conception and hospital admissions for adverse events.
Results
Overall, 181 participants followed the protocol and 169 (93.3%) participants had a complete expulsion of the gestational sac by the second visit (day 14). Twelve (6.6%) failed the treatment and 1 had an adverse event of heavy vaginal bleeding requiring dilatation and curettage. Despite the expulsion of the gestational sac, 29 cases (17.1%) at subsequent follow-up were diagnosed as retained products of conception based on ultrasound assessment of thickened endometrium.
Conclusions
Pretreatment with mifepristone followed by 2 doses of misoprostol with a 14-day follow-up resulted in a high expulsion rate and is a safe management option for EPL.
{"title":"The Success of Mifepristone and Misoprostol in the Management of Early Pregnancy Loss at a Community Hospital: A Prospective Study","authors":"","doi":"10.1016/j.jogc.2024.102604","DOIUrl":"10.1016/j.jogc.2024.102604","url":null,"abstract":"<div><h3>Objectives</h3><p>This prospective single-arm study was conducted to understand the expulsion rate of the gestational sac in the management of early pregnancy loss (EPL).</p></div><div><h3>Methods</h3><p>We recruited 441 participants; 188 met the eligibility criteria. Participants were 18 years of age and older who experienced a confirmed EPL (<12 weeks gestational age) defined by an intrauterine pregnancy with a non-viable embryonic or anembryonic gestational sac with no fetal heart activity. Participants were given 200 mg of mifepristone pre-treatment orally followed by 2 doses of misoprostol 800 μg vaginally after 24 and 48 hours. Participants were seen in follow-up on day 14 to confirm the absence of a gestational sac, classified as treatment success. For failed treatment (defined by retained gestational sac), we offered expectant management or a third dose of misoprostol and/or dilatation and curettage. We followed all participants for 30 days. We collected data on overtreatment for retained products of conception and hospital admissions for adverse events.</p></div><div><h3>Results</h3><p>Overall, 181 participants followed the protocol and 169 (93.3%) participants had a complete expulsion of the gestational sac by the second visit (day 14). Twelve (6.6%) failed the treatment and 1 had an adverse event of heavy vaginal bleeding requiring dilatation and curettage. Despite the expulsion of the gestational sac, 29 cases (17.1%) at subsequent follow-up were diagnosed as retained products of conception based on ultrasound assessment of thickened endometrium.</p></div><div><h3>Conclusions</h3><p>Pretreatment with mifepristone followed by 2 doses of misoprostol with a 14-day follow-up resulted in a high expulsion rate and is a safe management option for EPL.</p></div>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141476837","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-21DOI: 10.1016/j.jogc.2024.102592
N. Muthuraman MD , Premila Abraham MSc, PhD
{"title":"Serum Tumour Necrosis Factor-α (TNF-α) and Lipid Profile in Gestational Diabetes Mellitus","authors":"N. Muthuraman MD , Premila Abraham MSc, PhD","doi":"10.1016/j.jogc.2024.102592","DOIUrl":"10.1016/j.jogc.2024.102592","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-15DOI: 10.1016/j.jogc.2024.102587
Jaclyn Del Pozzo DO, MS , Insaf Kouba MD , Nicholas Dilena DO , Alexandra Peyser MD , Julia Katz MD , Matthew J. Blitz MD, MBA
{"title":"Maternal and Neonatal Outcomes Associated With Route of Progesterone Administration in Pregnancies Following a Single Euploid Frozen Embryo Transfer","authors":"Jaclyn Del Pozzo DO, MS , Insaf Kouba MD , Nicholas Dilena DO , Alexandra Peyser MD , Julia Katz MD , Matthew J. Blitz MD, MBA","doi":"10.1016/j.jogc.2024.102587","DOIUrl":"10.1016/j.jogc.2024.102587","url":null,"abstract":"","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141419535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-13DOI: 10.1016/j.jogc.2024.102585
Phoebe Friesen, Wan-Li Sun, Sarah Towle
Objectives: This study investigates experiences of medical students across Canada related to consent for educational sensitive (i.e., pelvic, rectal) exams under anesthesia (EUAs).
Methods: A bilingual online questionnaire was developed and distributed to medical students across Canada.
Results: Of 134 respondents, 63% had performed a pelvic EUA, 35% a rectal EUA, and 11% another sensitive EUA during their training. For those who had performed pelvic EUA, 28% were unsure if consent had taken place, 26% reported no specific consent, 20% reported specific consent, and 25% had mixed experiences of consent. For rectal EUAs, 48% reported no specific consent, 37% were unsure if consent had taken place, 13% reported that there had been specific consent, and 2% reported mixed experiences. Most respondents were uncomfortable (36%) or not sure if they were comfortable (32%) with how the consent process was handled for student pelvic EUAs; 31% were comfortable. In open-ended responses, respondents described experiences related to variability, discomfort, and authority.
Conclusions: Non-consensual educational sensitive EUAs continue to take place in medical training across Canada, although practices of consent are highly variable. The majority of respondents reported being uncomfortable or unsure if they were comfortable with how consent for educational sensitive EUAs was practised during their training, and some respondents struggled to express their discomfort given the power dynamics at play.
{"title":"Consent and Educational Sensitive Exams on Anesthetized Patients: Experiences of Medical Students Across Canada.","authors":"Phoebe Friesen, Wan-Li Sun, Sarah Towle","doi":"10.1016/j.jogc.2024.102585","DOIUrl":"10.1016/j.jogc.2024.102585","url":null,"abstract":"<p><strong>Objectives: </strong>This study investigates experiences of medical students across Canada related to consent for educational sensitive (i.e., pelvic, rectal) exams under anesthesia (EUAs).</p><p><strong>Methods: </strong>A bilingual online questionnaire was developed and distributed to medical students across Canada.</p><p><strong>Results: </strong>Of 134 respondents, 63% had performed a pelvic EUA, 35% a rectal EUA, and 11% another sensitive EUA during their training. For those who had performed pelvic EUA, 28% were unsure if consent had taken place, 26% reported no specific consent, 20% reported specific consent, and 25% had mixed experiences of consent. For rectal EUAs, 48% reported no specific consent, 37% were unsure if consent had taken place, 13% reported that there had been specific consent, and 2% reported mixed experiences. Most respondents were uncomfortable (36%) or not sure if they were comfortable (32%) with how the consent process was handled for student pelvic EUAs; 31% were comfortable. In open-ended responses, respondents described experiences related to variability, discomfort, and authority.</p><p><strong>Conclusions: </strong>Non-consensual educational sensitive EUAs continue to take place in medical training across Canada, although practices of consent are highly variable. The majority of respondents reported being uncomfortable or unsure if they were comfortable with how consent for educational sensitive EUAs was practised during their training, and some respondents struggled to express their discomfort given the power dynamics at play.</p>","PeriodicalId":16688,"journal":{"name":"Journal of obstetrics and gynaecology Canada","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2024-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141327612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}